ARTICLE | Emerging Company Profile
Longwood launches Immunitas with $39M and single-cell genomics platform
Immunitas is harnessing single-cell analysis to identify new immune targets for cancer
November 22, 2019 1:04 AM UTC
Updated on Nov 22, 2019 at 2:48 AM UTC
With $39M series A, Immunitas is harnessing single-cell analysis to identify new immune targets for cancer.
Immunitas Therapeutics emerged from stealth mode on Thursday with a $39 million series A round and a single-cell genomics platform to identify novel targets for mAbs that boost antitumor immunity. ...